Public Profile

Mesoblast Limited

Mesoblast Limited, an innovative leader in regenerative medicine, is headquartered in Australia and operates extensively across North America, Europe, and Asia. Founded in 2004, the company has made significant strides in developing advanced cell-based therapies, particularly in the fields of orthopaedics, cardiovascular diseases, and inflammatory conditions. Mesoblast's core products, including its proprietary allogeneic cell therapy platforms, are designed to address unmet medical needs with unique mechanisms of action that promote healing and tissue regeneration. The company has achieved notable milestones, including successful clinical trials and partnerships that enhance its market position in the biotechnology sector. With a commitment to transforming patient care, Mesoblast continues to be at the forefront of innovation in regenerative medicine.

DitchCarbon Score

How does Mesoblast Limited's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.

9

Industry Average

Mean score of companies in the Health Services industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.

2

Industry Benchmark

Mesoblast Limited's score of 9 is higher than 76% of the industry. This can give you a sense of how well the company is doing compared to its peers.

76%

Mesoblast Limited's reported carbon emissions

Mesoblast Limited, headquartered in Australia, currently does not have publicly available carbon emissions data or specific reduction targets. Without emissions figures, it is challenging to assess their carbon footprint or climate commitments. However, the absence of data may indicate a need for enhanced transparency in their environmental impact reporting. As the biopharmaceutical industry increasingly prioritises sustainability, Mesoblast may benefit from establishing clear climate commitments and reduction initiatives to align with industry standards and stakeholder expectations.

Industry emissions intensity

Very low
Low
Medium
High
Very high
Some industries are more carbon intensive than others. Mesoblast Limited's primary industry is Health and social work services (85), which is low in terms of carbon intensity compared to other industries.

Location emissions intensity

Very low
Low
Medium
High
Very high
The carbon intensity of the energy grid powering a company's primary operations has a strong influence on its overall carbon footprint. Mesoblast Limited is headquartered in AU, which has a rank of very high, indicating very high grid carbon intensity.

Reduction initiatives & disclosure networks

Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.

Mesoblast Limited is not committed to any reduction initiatives we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.

Science Based Targets Initiative
Carbon Disclosure Project
The Climate Pledge
UN Global Compact
Carbon Disclosure Project
The Climate Pledge
UN Global Compact

Similar Organizations

Xtant Medical Holdings, Inc.

US
Health and social work services (85)
Updated 5 days ago

Axogen

US
Other business services (74)
Updated 5 days ago

American CryoStem Corporation

US
Health and social work services (85)
Updated 5 days ago

Derma Sciences, Inc.

US
Chemicals nec
Updated 5 days ago
DitchCarbon Score

Orthofix

US
Medical, precision and optical instruments, watches and clocks (33)
Updated 2 days ago

Compugen Ltd.

IL
Health and social work services (85)
Updated 5 days ago

Where does DitchCarbon data come from?

Discover our data-driven methodology for measuring corporate climate action and benchmarking against industry peers